J&J’s Covid-19 vaccine has something its closest competitors lack
Johnson & Johnson is starting a Phase 3 trial of its Covid-19 vaccine today, making it the fourth company to do so. But unlike its nearest rivals, J&J has a vaccine that may require just one dose instead of two, which could be a differentiation in the months to come.
As the Boston Globe reports, J&J is planning to enroll up to 60,000 volunteers in the U.S. and abroad to test its vaccine, which uses a harmless virus to deliver a key protein found on the surface of SARS-CoV-2. Like its competitors, the company plans to conduct regular analyses of the vaccine’s safety and efficacy as the trial progresses, opening the door for an early conclusion if it appears especially effective.
J&J’s Phase 3 trial is about two months behind those of Moderna and the partnership of Pfizer and BioNTech, and it trails AstraZeneca’s U.S. study, which remains on hold after a safety issue. Each of those vaccines requires two administrations a few weeks apart. That means J&J’s one-dose vaccine, if it works, could inoculate twice as many people and avoid the risk that patients don’t return for a second vaccination.
As the Boston Globe reports, J&J is planning to enroll up to 60,000 volunteers in the U.S. and abroad to test its vaccine, which uses a harmless virus to deliver a key protein found on the surface of SARS-CoV-2. Like its competitors, the company plans to conduct regular analyses of the vaccine’s safety and efficacy as the trial progresses, opening the door for an early conclusion if it appears especially effective.
J&J’s Phase 3 trial is about two months behind those of Moderna and the partnership of Pfizer and BioNTech, and it trails AstraZeneca’s U.S. study, which remains on hold after a safety issue. Each of those vaccines requires two administrations a few weeks apart. That means J&J’s one-dose vaccine, if it works, could inoculate twice as many people and avoid the risk that patients don’t return for a second vaccination.
.png)
No hay comentarios:
Publicar un comentario